Ignite Creation Date:
2024-05-05 @ 9:45 PM
Last Modification Date:
2024-10-26 @ 10:09 AM
Study NCT ID:
NCT00953511
Status:
COMPLETED
Last Update Posted:
2016-10-21
First Post:
2009-08-03
Brief Title:
Cologne Esophageal Response Prediction Study CERP-Study
Sponsor:
Elfriede Bollschweiler
Organization:
University of Cologne
Study Overview
Official Title:
Prospective Study to Analyze the Predictive Role of Factors Implicated in the Signaling Pathway of ERCC1 in Response to Treatment With Neoadjuvant Radiochemotherapy in Patients With Esophageal Cancer
Status:
COMPLETED
Status Verified Date:
2016-10
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
CERP
Brief Summary:
RATIONALE The prognosis of patients with advanced esophageal cancer may be improved by preoperative chemoradiation But only those patients have a benefit from this additional therapy whose tumor shows a response after chemoradiation Molecular markers may help to identify before starting the therapy those patients who response
PURPOSE This is the first prospective clinical trial to study the impact of ERCC1 to predict histopathological response to neoadjuvant radiochemotherapy RTxCTx in patients with cancer of the esophagus
PURPOSE This is the first prospective clinical trial to study the impact of ERCC1 to predict histopathological response to neoadjuvant radiochemotherapy RTxCTx in patients with cancer of the esophagus
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None